Week In Review: 3 More China Biopharmas Planning Hong Kong IPOs

Mabpharm Limited, a Taizhou biotech, will IPO in Hong Kong, the eleventh pre-revenue China biopharma to be approved to list there. Mabpharm is developing a portfolio of nine biosimilars, which it hope…
( read original story …)



Related Post